CHICAGO, March 14, 2011 /PRNewswire/ — Developed by inventor
Lawrence F. Glaser and represented by ICAP Ocean
Tomo, this technology will be auctioned off at ICAP Ocean
Tomo’s Spring 2011 Live IP Auction on March 31, 2011 in New
York City.
(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)
Key Characteristics & Benefits
This patent discloses the following:
- The use of genetically modified erythrocytes/red blood cells
(RBC) for treating and preventing viral infections. Modified cells
can also be generated through non-recombinant low-cost means, such
as with ghosting techniques using mature patient or donor
cells. - A desired protein receptor/coreceptor may be introduced into
precursor cells using a gene transfer technique, such as
transfection, transduction, and gene gun. These modified precursor
cells can then be cultured in a suitable environment to generate
the desired erythrocyte having a specific protein receptor complex,
used as a trap for treating a target viral infection. - The disclosed erythrocytes comprise HIV receptors capable of
mediating HIV entry into the modified cells. When these modified
erythrocytes are administered to an HIV+ patient, the erythrocytes
attract and absorb HIV, uncloaking each viral particle preventing
further viral infection through direct depletion of viral
load. - The entrapped virus is subsequently degraded and deactivated
within the erythrocytes, assuring entrapment. Red Cells are
eliminated through the natural cycle, Erythrophagocytosis, shown in
research studies to completely disintegrate any payload. - The modified erythrocytes can be prepared from the erythrocyte
precursor cells isolated from peripheral blood, bone marrow,
umbi‘/>”/>
SOURCE